The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma.
The prognostic significance of minimal residual disease (MRD) in the early phases of chemotherapy was examined in 36 dogs with multicentric high-grade B-cell lymphoma. Sequences of immunoglobulin heavy chain (IgH) gene fragments from lymphoma cells were amplified and used to design allele-specific primers and probes for real-time PCR. The dogs were treated with a 6-month modified version of the University of Wisconsin-Madison chemotherapy protocol (UW-25) and evaluated for the MRD level at weeks 6 and 11 of UW-25. Of the 31 dogs that remained on the protocol at week 11, 14 were found to be MRD negative (<10tumour cells/10(5) peripheral blood mononuclear cells [PBMCs]), whereas the other 17 were MRD positive (⩾10tumour cells/10(5) PBMCs). The progression-free survival of the dogs with MRD-negative status at week 11 (median, 337days) was significantly longer than that of the MRD-positive dogs at the same time point (median, 196days) (P=0.0002). These results indicate the clinical significance of MRD as a prognostic marker in the early phase of chemotherapy.
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Masahiko
M
Sato
Jumpei
J
Yamzaki
Yuko
Y
Goto-Koshino
Masashi
M
Takahashi
Yasuhito
Y
Fujino
Koichi
K
Ohno
Hajime
H
Tsujimoto
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004334:Drug Administration Schedule; D005260:Female; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000662:veterinary*; D008297:Male
D000970:Antineoplastic Agents